Literature DB >> 11396445

The hemophilias--from royal genes to gene therapy.

P M Mannucci1, E G Tuddenham.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11396445     DOI： 10.1056/NEJM200106073442307

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  244 in total

1.  Thrombin activatable fibrinolysis inhibitor activation and bleeding in haemophilia A.

Authors:  J H Foley; M E Nesheim; G E Rivard; K E Brummel-Ziedins
Journal:  Haemophilia       Date:  2011-09-20       Impact factor: 4.287

2.  Unsuspected haemophilia in children with a single swollen joint.

Authors:  Beatrice Nolan; Vicky Vidler; Ajay Vora; Michael Makris
Journal:  BMJ       Date:  2003-01-18

3.  Determinants of drug costs in hopitalised patients with haemophilia: impact of recombinant activated factor VII.

Authors:  Jean Philippe Galanaud; Nathalie Pelletier-Fleury; Hélène Logerot-Lebrun; Thierry Lambert
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

4.  Plasma-derived versus recombinant Factor VIII concentrates for the treatment of haemophilia A: recombinant is better.

Authors:  Massimo Franchini
Journal:  Blood Transfus       Date:  2010-10       Impact factor: 3.443

5.  Recommendations for the implementation of a Patient Blood Management programme. Application to elective major orthopaedic surgery in adults.

Authors:  Stefania Vaglio; Domenico Prisco; Gianni Biancofiore; Daniela Rafanelli; Paola Antonioli; Michele Lisanti; Lorenzo Andreani; Leonardo Basso; Claudio Velati; Giuliano Grazzini; Giancarlo M Liumbruno
Journal:  Blood Transfus       Date:  2015-12-15       Impact factor: 3.443

Review 6.  Octocog alfa, plasma/albumin-free method.

Authors:  Paul L McCormack; Greg L Plosker
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 7.  Recombinant factor VIIa (Eptacog Alfa): a review of its use in congenital or acquired haemophilia and other congenital bleeding disorders.

Authors:  M Asif A Siddiqui; Lesley J Scott
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 8.  The genetic and molecular bases of monogenic disorders affecting proteolytic systems.

Authors:  I Richard
Journal:  J Med Genet       Date:  2005-07       Impact factor: 6.318

9.  Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant.

Authors:  Lindsey A George; Spencer K Sullivan; Adam Giermasz; John E J Rasko; Benjamin J Samelson-Jones; Jonathan Ducore; Adam Cuker; Lisa M Sullivan; Suvankar Majumdar; Jerome Teitel; Catherine E McGuinn; Margaret V Ragni; Alvin Y Luk; Daniel Hui; J Fraser Wright; Yifeng Chen; Yun Liu; Katie Wachtel; Angela Winters; Stefan Tiefenbacher; Valder R Arruda; Johannes C M van der Loo; Olga Zelenaia; Daniel Takefman; Marcus E Carr; Linda B Couto; Xavier M Anguela; Katherine A High
Journal:  N Engl J Med       Date:  2017-12-07       Impact factor: 91.245

Review 10.  Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency.

Authors:  Timothy C Nichols; Aaron M Dillow; Helen W G Franck; Elizabeth P Merricks; Robin A Raymer; Dwight A Bellinger; Valder R Arruda; Katherine A High
Journal:  ILAR J       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.